Demographic, clinical, and biological parameters depending on Crohn’s disease behaviour*
| B1 | B2 | B3 | p Value | |
|---|---|---|---|---|
| *B1, non-stricturing non-penetrating; B2, stricturing; B3, penetrating, according to the Vienna classification, five years after diagnosis. | ||||
| p values correspond to univariate analysis for each parameter using either χ2 or Kruskal Wallis tests, as required. | ||||
| CD, Crohn’s disease; ASCA, antisaccharomyces cerevisiae antibodies. | ||||
| *Mean (SD). | ||||
| Age at diagnosis (%) (n=163) | n=110 | n=18 | n=35 | |
| <40 years (A1) | 82.0 | 88.9 | 94.3 | 0.18 |
| >40 years (A2) | 18.0 | 11.1 | 5.7 | |
| Location of the disease (%) (n=163) | n=110 | n=18 | n=35 | |
| Ileal (L1) | 38.2 | 89.9 | 45.7 | 0.0003 |
| Colonic (L2) | 33.6 | 0 | 22.9 | |
| Ileocolonic (L3) | 23.6 | 0 | 28.6 | |
| Upper gastrointestinal tract (L4) | 4.6 | 11.1 | 2.9 | |
| Sex (%) (n=163) | n=110 | n=18 | n=35 | |
| Male | 34.5 | 22.2 | 37.1 | 0.53 |
| Female | 65.5 | 77.8 | 62.9 | |
| Smoking habit (%) (n=124) | n=79 | n=16 | n=29 | |
| Yes | 41.8 | 62.5 | 65.5 | 0.052 |
| No | 58.2 | 37.5 | 34.5 | |
| Familial disease (%) (n= 156) | n=106 | n=16 | n=34 | |
| Yes | 17.0 | 31.3 | 5.9 | 0.07 |
| No | 83.0 | 68.7 | 94.1 | |
| ASCA (%) (n=90) | n=54 | n=14 | n=22 | |
| Positive | 64.8 | 35.7 | 72.7 | 0.044 |
| Negative | 35.2 | 64.3 | 27.3 | |
| NOD2/CARD15 (%) (n=101) | n=48 | n=18 | n=35 | |
| Wild-type | 47.9 | 44.4 | 68.6 | 0.34 |
| Heterozygotes | 39.6 | 38.9 | 22.8 | |
| Homozygotes and compound heterozygotes | 12.5 | 16.7 | 8.6 | |
| Steroid courses (No/year) (n=126) | n=83 | n=15 | n=28 | |
| 0.35 (0.48)* | 0.23 (0.26)* | 0.69 (0.71)* | 0.026 | |
| Flares of CD (No/year) (n=126) | n=83 | n=15 | n=28 | |
| 0.74 (0.77)* | 0.68 (0.22)* | 1.53 (0.82)* | <0.0001 | |
| Azathioprine treatment (months/year) (n=145) | n=99 | n=16 | n=30 | |
| 0.25 (0.12)* | 0.4 (0.4)* | 0.16 (0.16)* | 0.84 | |